Four lines of evidence (clinical findings, epidemiology, inhibition of tumor growth together with prolongation of survival time, and mechanism of action) which suggest that certain phenothiazines, particularly chlorpromazine, possess a range of anti-neoplastic activities in man and in rodents which has not been generally recognised are reviewed and discussed. Chlorpromazine interferes with energy production in sensitive tumours; the mode of action appears to correspond to autooxidative cellular injury, a common form of cell death.
Get full access to this article
View all access options for this article.
References
1.
AlströmC.H.: Mortality in mental hospitals with especial regard to tuberculosis.Acta Psych. Scand., Suppl., 24: 1–422, 1942.
2.
AutorA.P.: Oxygen toxicity in eukaryotes. In: The Biology and Chemistry of Active Oxygen.BannisterJ.V., BannisterW.H. (eds.), Developments in Biochemistr, vol. 26, pp. 139–145, Elsevier, Amsterdam, 1984.
3.
BabigianH.M., OdoroffC.L.: The mortality experience of a population with psychiatric illness.Am. J. Psychiatry, 126: 470–480, 1969.
4.
BaldwinJ.A.: Schizophrenia and physical disease.Psychol. Med., 9: 611–618, 1979.
5.
BalentineJ.D.: Pathology of oxygen toxicity.Academic Press, New York, 1982.
6.
BaiterM.B., LevineJ.: The nature and extent of psychotropic drug usage in the United States.Psychopharmacol. Bull., 5: 3–13, 1969.
7.
BelkinM., HardyW.G.: Effect of reserpine and chlorpromazine on sarcoma 37.Science, 125: 233–234, 1957.
8.
BlochC.: Un centre psychiatrique à New York. Organisation, traitement et enseignement à la Payne Whitney Clinic.Acta Neurol. Psychiatr. Belg., 57: 27–66, 1957.
9.
BrillH., PattonR.E.: Analysis of population reduction in New York State mental hospitals during the first four years of large-scale therapy with psychotropic drugs.Am. J. Psychiatry, 116: 495–508, 1959.
10.
CavanaughD.J.: Oxidation of chlorpromazine by peroxidase and catalase.Science, 125: 1040–1041, 1957.
11.
ChorazyM.: Effect of chlorpromazine on Crocker sarcoma and Ehrlich ascites carcinoma.Nature, 184: 200–201, 1959.
12.
CohenI.K., ThomasC.G.: Enhancement of the effectiveness of chemotherapeutic agents by modification of cell membrane permeability.Proc. Am. Assoc. Cancer Res., 4: 11, 1963.
13.
ColeyW.B.: Further observations upon the treatment of malignant tumours with the toxins of erysipelas and Bacillus prodigiosus, with a report of 160 cases.Johns Hopkins Hosp. Bull., 7: 157–162, 1896.
14.
CranstonE.M.: Effects of some tranquillizers on a mammary adenocarcinoma in mice.Cancer Res., 18: 897–899, 1958.
15.
CsataryL.K.: Chlorpromazine and cancer.Lancet, 2: 338–339, 1972.
16.
DelayJ., DenikerP., HarlJ.M.: Utilisation en thérapeutique psychiatrique d'une phénothiazine d'action centrale élective (4560 RP).Ann. Méd. Psychol., Paris, 110(2): 112–117, 1952.
17.
DenberH.C.B., BirdE.G.: Chlorpromazine in the treatment of mental illness IV: Final results with analysis of data on 1,523 patients.Am. J. Psychiatry, 113: 972–978, 1957.
18.
DerogatisL.R., FeldsteinM., MorrowG., SchmaleA., SchmittM., GatesC., MuraskiB., HollandJ., PenmanD., MelisaratosN., EnelowA.J., McKinney AdlerL.: A survey of psychotropic drug prescriptions in an oncology population.Cancer, 44: 1919–1924, 1979.
19.
DominoE.F., HudsonR.D., ZografiG.: Substituted phenothiazines: pharmacology and chemical structure. In: Drugs Affecting the Central Nervous System.BurgerA. (ed.), Vol. 2, pp. 327–397. Edward Arnold, London, and Marcel Dekker, New York, 1968.
EckmannF., ImmichH., ScheurlenH.R.: Können Neuroleptika Krebs verhüten?Pharmakopsychiatrie, 8: 357–365, 1975.
22.
Editorial.Mind and cancer.Lancet, 1: 706–707, 1979.
23.
EickeW.J.: Günstige Verläufe bei Karzinompatienten unter zusätzlicher Behandlung mit Phenothiazinderivaten.Med. Klin., 68: 1015–1018, 1973.
24.
FoxB.H.: Cancer death risk in hospitalized mental patients.Science, 201: 966–968, 1978.
25.
FoxB.H., HowellM.A.: Cancer risk among psychiatric patients: a hypothesis.Int. J. Epidemiol., 3: 207–208, 1974.
26.
FriendD.G., WellsJ.C.: The clinical use of chlorpromazine.Am. Pract. Digest. Treatment, 6: 698–703, 1955.
27.
GerberI.E., BernheimA.I.: Morphologic study of the reactivity of mouse sarcoma 180 to bacterial filtrates.Arch. Pathol., 26: 971–983, 1938.
28.
GielR., DijkS., van Weerden-DijkstraJ.R.: Mortality in the long-stay population of all Dutch mental hospitals.Acta Psychiatr. Scand., 57: 361–368, 1978.
29.
GoodmanL.S., GilmanA.: The pharmacological basis of therapeutics, 5th ed., p. 163. Macmillan Publishing Co., New York, 1975.
30.
GordonR.A., CampbellM.: The use of chlorpromazine in intractable pain associated with terminal carcinoma.Canad. Med. Assoc. J., 75: 420–421, 1956.
31.
Grossarth-MaticekR., Frentzel-BeymeR., BeckerN.: Cancer risks associated with life events and conflict solution.Cancer Det. Prev., 7: 201–209, 1984.
32.
HerrmanH.E., BaldwinJ.A., ChristieD.: A record-linkage study of mortality of general hospital discharge in patients diagnosed as schizophrenic.Psychol. Med., 13: 581–593, 1983.
33.
HilfR., BellC., GoldenbergH., MichelI.: Effect of fluphenazine HCl on R3230AC mammary carcinoma and mammary glands of the rat.Cancer Res., 31: 1111–1117, 1971.
34.
HoshiA., KanzawaF., KuretaniK.: Antitumour activity of psychotropic drugs and their synergic action with cyclophosphamide.Chem. Pharm. Bull., 17: 848–850, 1969.
JonesG.R.N.: Early mitochondrial damage in the induction of haemorrhagic necrosis in the Crocker sarcoma (S180) by endotoxin.J. Cancer Res. Clin. Oncol., 93: 245–254, 1979.
37.
JonesG.R.N.: Early cutback in chemical energy production in the Crocker sarcoma (S180) undergoing haemorrhagic necrosis as a result of endotoxin administration.J. Cancer Res. Clin. Oncol., 96: 53–64, 1980.
38.
JonesG.R.N.: Interference with energy production as a means of causing injury to a human pancreatic carcinoma.Oncology, 40: 259–262, 1983.
39.
JonesG.R.N., BaumR., MerkelR., SchwarzM.: Distrurbance to energy production in vivo caused hy hormones and sympathomimetics in the S180 sarcoma, with consequent drug-induced necrosis.Biochem. Soc. Trans., 8: 105, 1980.
40.
JonesG.R.N., EllisR., FrohnM.J.N.: Drug-induced interference with energy metabolism in the S180 sarcoma: a new principle in the production of selective tumour injury.Oncodev. Biol. Med., 2: 155–164, 1981.
41.
JonesG.R.N., FrohnM.J.N.: An injurious effect of chlorpromazine in the murine S180 sarcoma (var CB) and its relevance to cancer treatment.Biochem. Soc. Trans., 12: 679–680, 1984.
42.
JonesG.R.N., FrohnM.J.N., BeckettA.H.: Liminal therapy: a strategy for the complete and selective destruction of malignant tissue in situ.Med. Hypothesis, 15: 349–359, 1984.
43.
KanzawaF., HoshiA., KuretaniK.: Relationship between antitumour activity and chemical structure in psychotropic agents.Gann, 61: 529–534, 1970.
44.
KanzawaF., HoshiA., KuretaniK.: Antitumour activity of haloacetylphenothiazines against ascites sarcoma-180.Gann, 63: 225–229, 1972.
45.
KatzJ., KunofskyS., PattonR.E., AllawayN.C.: Cancer mortality among patients in New York mental hospitals.Cancer, 20: 2194–2199, 1967.
46.
KerrT.A., SchapiraK., RothM.: The relationship between premature death and affective disorders.Br. J. Psychiatry, 115: 1277–1282, 1969.
47.
Kinross-WrightV.: Chlorpromazine - a major advance in psychiatric treatment.Postgrad. Med., 16: 297–299, 1954.
48.
Kinross-WrightV.: Chlorpromazine in psychiatric disorders.Med. Clin. North Am., 41: 295–306, 1957.
49.
KokkorisP., KordasS., NikolopoulosP., YannirisM.: The results of chlorpromazine treatment with chronic psychoses in Dromokaition.J. Nerv. Ment. Dis., 125: 102–111, 1957.
50.
LeShanL.: Psychological states as factors in the development of malignant disease: a critical review.J. Natl. Cancer Inst., 22: 1–18, 1959.
51.
LitteralE.B., WilkinsonW.E.: The advantages, disadvantages and limitations of the use of chlorpromazine as a substitute for certain somatic treatment methods in psychiatry.Psychiat. Res. Rep., 1: 63–71, 1955.
52.
LomasJ., BoardmanR.H., MarkoweM.: Complications of chlorpromazine therapy in 800 mental-hospital patients.Lancet, 1: 1144–1147, 1955.
53.
LucasJ., AlbertS.N., BatemanJ.C., KloppC.T.: Thorazine as an aid in management of cancer patients.Proc. Am. Assoc. Cancer Res., 1(2): 30, 1954.
54.
LührsW.: Über die Kombinationsbehandlung mit entkoppelnden Substanzen bei malignen Tumoren.Krebsarzt, 17: 405–410, 1962.
55.
LührsW., BacigalupoG., KadenbachB., HeiseE.: Der Einfluss von Chlorpromazin auf die oxydative Phosphorylierung von Tumormitochondrien.Experientia, 15: 376–377, 1959.
56.
MalitzS., HochP.H., LesseS.: A two-year evaluation of chlorpromazine in clinical research and practice.Am. J. Psychiatry, 113: 540–545, 1956.
57.
MalzbergB.: Mortality among patients with mental disease.State Hospitals Press, Utica, New York, 1934.
58.
MalzbergB.: Mortality from cancer among patients with mental disease in the New York civil state hospitals.Psychitr. Q., 24(suppl.): 73–79, 1950.
59.
MasonR.P.: Free-radical intermediates in the metabolism of toxic chemicals. In: Free Radicals in Biology, PryorW.A. (ed.), Vol. 5, pp. 161–222. Academic Press, New York and London, 1982.
60.
MoullinC.M.: The treatment of sarcoma and carcinoma by injections of mixed toxins.John Bale sons & Danielsson, London, 1898.
61.
MoyerJ.H., Kinross-WrightV., FinneyR.M.: Chlorpromazine as a therapeutic agent in clinical medicine.Arch. Int. Med., 95: 202–218, 1955.
62.
NautsH.C.: Beneficial effects of immunotherapy (bacterial toxins) on sarcoma of the soft tissues, other than lymphosarcoma. Monograph 16, Cancer Research Institute, New York, 1975.
63.
NautsH.C.: Beneficial effects of acute concurrent infection, inflammation, fever or immunotherapy (bacterial toxins) on ovarian and uterine cancer. Monograph 17, Cancer Research Institute, New York, 1977.
64.
ØdegårdØ.: Mortality in Norwegian mental hospitals.Acta Genet., 2: 141–173, 1951.
PaulesuF., VargiuL.: Attività antiproliferativa di derivati fenotiazinici. Esperienze sulla radice del lupino e sul carcinosarcoma di Walker nel ratto.Giorn. Ital. Chemioter., 2: 70–74, 1955.
67.
PerrinG.M., PierceI.R.: Psychosomatic aspects of cancer.Psychosom. Med., 21: 397–421, 1959.
68.
PollackB.: Preliminary report on 500 patients treated with thorazine at Rochester State Hospital.Psychiatr. Q., 29: 439–456, 1955.
69.
RassidakisN.C., KelepourisM., FoxS.: Malignant neoplasms as a cause of death among psychiatric patients.Int. Ment. Hlth. Res. Newslett., 13(2): 6, 1971.
70.
RassidakisN.C., KelepourisM., GoulisK., MaraiossefidisK.: Malignant neoplasms as a cause of death among psychiatric patients.Int. Ment. Hlth. Res. Newslett., 14(2): 1–3, 1972.
71.
RassidakisN.C., KondakisX., PapanastassiouA., MichalakeasA.: Withdrawal of antipsychotic drugs from chronic psychiatric patients.Bull. Menn. Clin., 34: 216–222, 1970.
72.
ReynoldsJ.E.F., PrasadA.B. (eds.), pp. 1509–1513, Martindale: the extra pharmacopoeia, 28th ed., Pharmaceutical Press, London, 1982.
73.
RockmoreL., ShatinL., FunkI.C.: Response of psychiatric patients to massive doses of thorazine: I. Behavioural and clinical analysis.Psychiatr. Q., 30: 189–203, 1956.
74.
SadoveM.S., LevinM.J., RoseR.F., SchwartzL., WittF.W.: Chlorpromazine and narcotics in the management of pain of malignant lesions.J. Am. Med. Assoc, 155: 626–628, 1954.
75.
ScheflenA.E.: Malignant tumours in the institutionalised psychotic population.AMA Arch. Neurol. Psychiatry, 66: 145–155, 1951.
76.
ShearM.J., PerraultA.: Chemical treatment of tumours. IX Reactions of mice with primary subcutaneous tumours to injection of a haemorrhage-producing bacterial polysaccharide.J. Natl. Cancer Inst., 4: 461–476, 1944.
77.
SigwaldJ., BouttierD.: Le chlorhydrate de chloro-3-(diméthylamino - 3′ - propyl)-10-phénothiazine en pratique neuro-psichiatrique courante.Ann. Méd., 54: 150–182, 1953.
78.
TrumpB.F., McDowellE.M., ArstilaA.V.: Cellular reaction to injury. In: Principles of Pathobiology, HillR.B., LaViaM.F. (eds.), 3rd ed., pp. 20–111, Oxford University Press, Oxford, 1980.
79.
TsuangM.T., WoolsonR.F., FlemingJ.A.: Schizophrenia and cancer death.Lancet, 1: 480–481, 1980.
80.
U.S. Patent 2,645,640. Phenthiazine derivatives, 5 pp., 1953.
81.
Van WoertM.H., PalmerS.H.: Inhibition of the growth of mouse melanoma by chlorpromazine.Cancer Res., 29: 1952–1955, 1969.
82.
WeinerN., HulsH.N.: Effect of chlorpromazine on levels of adenine nucleotides and creatine phosphate of brain.J. Neurochem., 7: 180–185, 1961.
83.
WilliamsP.: Psychotropic drug prescribing.Practitioner, 227: 77–81, 1983.
